The Week in Review: Jinhe Biotech Stages $79 Million IPO in Shenzhen
Jinhe Biotechnology of Inner Mongolia raised $78.6 million in an IPO on the Shenzhen’s SME Exchange; Tianjin Joint Academy of Biotechnology and Medicine (TJAB) formed a JV with Australia’s Antisense Therapeutics to develop ANP’s multiple sclerosis drug; Lee’s Pharma of Hong Kong bought China rights to a novel clinical-stage peptide from RegeneRx Biopharma; Chengdu Hoist is selling its veterinary biological business; the Wuhan Institute of Biological Products (WIBF) formed a vaccine collaboration with Refine Technology of the US; China Health Resource announced a new TCM migraine medication built around Dahurian Angelica; Shanghai Jia Fu Medical Apparatus completed the dosing of two patients with a stem cell treatment developed by MediStem of the US; and Ironwood Pharma filed to start a China Phase III trial of linaclotide in patients with irritable bowel syndrome. More details…. Stock Symbols: (SHE: 002688) (ASX: ANP) (HK: 950) (OTCBB: RGRX) (SHE: 000790) (OTCBB: CHRI) (PinkSheets: MEDS) (NSDQ: IRWD) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here